New app could cut phone calls for cancer patients

NCT ID NCT06371911

Completed Symptom relief Sponsor: Centre Francois Baclesse Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether a digital platform called Cureety could reduce the number of phone calls hospital staff need to make to cancer patients before their injectable treatments. 192 adults starting injectable cancer therapy in France were randomly assigned to usual care or usual care plus Cureety. The platform lets patients report symptoms and test results online, potentially flagging only those who need a call.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cureety telemonitoring platform
What this could lead to: If successful, this could reduce hospital staff workload and improve patient convenience during cancer treatment monitoring.
What could go wrong: This is a completed study, but the results are not yet widely known. The benefit may be limited to patients comfortable with technology.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADULT PATIENTS INITIATING INJECTABLE ANTICANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADULT PATIENTS INITIATING INJECTABLE ANTICANCER

Contacts and locations

Locations

Centre François Baclesse

Caen, 14000, France
Centre de Radiothérapie et Oncologie Médicale d'Osny

Osny, France
Centre hospitalier de Bligny

Bligny, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.